This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Diabetes Mellitus, Type 2
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
-
Research Site, Mobile, Alabama, United States, 36608
Research Site, Sheffield, Alabama, United States, 35660
Research Site, Vestavia Hills, Alabama, United States, 35216
Research Site, Tucson, Arizona, United States, 85710
Research Site, Little Rock, Arkansas, United States, 72205
Research Site, Newport Beach, California, United States, 92660
Research Site, Sacramento, California, United States, 95821
Research Site, Tustin, California, United States, 92780
Research Site, Waterbury, Connecticut, United States, 06708
Research Site, Edgewater, Florida, United States, 32132
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
AstraZeneca,
2026-01-06